"briakinumab" meaning in All languages combined

{
  "etymology_templates": [
    {
      "args": {
        "1": "en",
        "2": "-kin-",
        "3": "-umab",
        "t1": "interleukin",
        "t2": "human monoclonal antibody"
      },
      "expansion": "-kin- (“interleukin”) + -umab (“human monoclonal antibody”)",
      "name": "af"
    }
  ],
  "etymology_text": "From -kin- (“interleukin”) + -umab (“human monoclonal antibody”).",
  "head_templates": [
    {
      "args": {
        "1": "-"
      },
      "expansion": "briakinumab (uncountable)",
      "name": "en-noun"
    }
  ],
  "lang": "English",
  "lang_code": "en",
  "pos": "noun",
  "senses": [
    {
      "categories": [
        {
          "kind": "other",
          "name": "English entries with incorrect language header",
          "parents": [
            "Entries with incorrect language header",
            "Entry maintenance"
          ],
          "source": "w"
        },
        {
          "kind": "other",
          "name": "English terms interfixed with -kin-",
          "parents": [],
          "source": "w"
        },
        {
          "kind": "other",
          "name": "English terms suffixed with -umab",
          "parents": [],
          "source": "w"
        },
        {
          "kind": "other",
          "name": "Pages with 1 entry",
          "parents": [],
          "source": "w"
        },
        {
          "kind": "other",
          "name": "Pages with entries",
          "parents": [],
          "source": "w"
        },
        {
          "kind": "topical",
          "langcode": "en",
          "name": "Pharmaceutical drugs",
          "orig": "en:Pharmaceutical drugs",
          "parents": [
            "Drugs",
            "Matter",
            "Pharmacology",
            "Chemistry",
            "Nature",
            "Biochemistry",
            "Medicine",
            "Sciences",
            "All topics",
            "Biology",
            "Healthcare",
            "Fundamental",
            "Health",
            "Body"
          ],
          "source": "w"
        }
      ],
      "examples": [
        {
          "ref": "2015 December 4, “Patient Preferences for Biologicals in Psoriasis: Top Priority of Safety for Cardiovascular Patients”, in PLOS ONE, →DOI:",
          "text": "As another interleukin 12/23 antagonist, briakinumab, was withdrawn from further development in part due to concerns about cardiovascular safety, discussion has also emerged on cardiovascular safety of ustekinumab.",
          "type": "quote"
        }
      ],
      "glosses": [
        "A human monoclonal antibody being developed to treat rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis."
      ],
      "id": "en-briakinumab-en-noun-XV7CiOhS",
      "links": [
        [
          "pharmacology",
          "pharmacology"
        ],
        [
          "human",
          "human"
        ],
        [
          "monoclonal antibody",
          "monoclonal antibody"
        ],
        [
          "rheumatoid arthritis",
          "rheumatoid arthritis"
        ],
        [
          "multiple sclerosis",
          "multiple sclerosis"
        ]
      ],
      "raw_glosses": [
        "(pharmacology) A human monoclonal antibody being developed to treat rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis."
      ],
      "tags": [
        "uncountable"
      ],
      "topics": [
        "medicine",
        "pharmacology",
        "sciences"
      ],
      "wikipedia": [
        "briakinumab"
      ]
    }
  ],
  "word": "briakinumab"
}

{
  "etymology_templates": [
    {
      "args": {
        "1": "en",
        "2": "-kin-",
        "3": "-umab",
        "t1": "interleukin",
        "t2": "human monoclonal antibody"
      },
      "expansion": "-kin- (“interleukin”) + -umab (“human monoclonal antibody”)",
      "name": "af"
    }
  ],
  "etymology_text": "From -kin- (“interleukin”) + -umab (“human monoclonal antibody”).",
  "head_templates": [
    {
      "args": {
        "1": "-"
      },
      "expansion": "briakinumab (uncountable)",
      "name": "en-noun"
    }
  ],
  "lang": "English",
  "lang_code": "en",
  "pos": "noun",
  "senses": [
    {
      "categories": [
        "English entries with incorrect language header",
        "English lemmas",
        "English nouns",
        "English terms interfixed with -kin-",
        "English terms suffixed with -umab",
        "English terms with quotations",
        "English uncountable nouns",
        "Pages with 1 entry",
        "Pages with entries",
        "en:Pharmaceutical drugs"
      ],
      "examples": [
        {
          "ref": "2015 December 4, “Patient Preferences for Biologicals in Psoriasis: Top Priority of Safety for Cardiovascular Patients”, in PLOS ONE, →DOI:",
          "text": "As another interleukin 12/23 antagonist, briakinumab, was withdrawn from further development in part due to concerns about cardiovascular safety, discussion has also emerged on cardiovascular safety of ustekinumab.",
          "type": "quote"
        }
      ],
      "glosses": [
        "A human monoclonal antibody being developed to treat rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis."
      ],
      "links": [
        [
          "pharmacology",
          "pharmacology"
        ],
        [
          "human",
          "human"
        ],
        [
          "monoclonal antibody",
          "monoclonal antibody"
        ],
        [
          "rheumatoid arthritis",
          "rheumatoid arthritis"
        ],
        [
          "multiple sclerosis",
          "multiple sclerosis"
        ]
      ],
      "raw_glosses": [
        "(pharmacology) A human monoclonal antibody being developed to treat rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis."
      ],
      "tags": [
        "uncountable"
      ],
      "topics": [
        "medicine",
        "pharmacology",
        "sciences"
      ],
      "wikipedia": [
        "briakinumab"
      ]
    }
  ],
  "word": "briakinumab"
}